Mesoblast Stock In The News

MESO Stock  USD 13.55  0.27  2.03%   
Our overall analysis of Mesoblast's news coverage and content from conventional and social sources shows investors' bearish mood towards Mesoblast. The specific impact of Mesoblast news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Mesoblast's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Mesoblast headlines in addition to utilizing other, more conventional financial analysis modules. Check out Mesoblast Backtesting and Mesoblast Hype Analysis.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Mesoblast Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
https://www.globenewswire.com/news-release/2025/02/19/3028585/0/en/Presenting-on-the-Emerging-Growth-Conference-79-Day-2-on-February-19-Register-Now.html
 Bullish
Yahoo News
Is Mesoblast (MESO) The Best Australian Stock To Buy According to Hedge Funds?
https://finance.yahoo.com/news/mesoblast-meso-best-australian-stock-215912422.html
 Bullish
Yahoo News
10 Best Long Term ASX Stocks To Invest In
https://finance.yahoo.com/news/10-best-long-term-asx-154919438.html
 Bullish
Yahoo News
11 Best ASX Stocks To Buy Now
https://finance.yahoo.com/news/11-best-asx-stocks-buy-115552280.html
 Bullish
Yahoo News
10 Best Australian Stocks To Buy
https://finance.yahoo.com/news/10-best-australian-stocks-buy-081134326.html
 Bullish
Yahoo News
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
https://finance.yahoo.com/news/mesoblast-meso-rare-pediatric-disease-163000364.html
 Bullish
Yahoo News
United States Food & Drug Administration...
https://finance.yahoo.com/news/united-states-food-drug-administration-233600152.html
 Bullish
Investors Business Daily at Macroaxis
Mesoblast (ASX:MSB) investors are sitting on a loss of 88% if they invested three years ago
https://finance.yahoo.com/news/mesoblast-asx-msb-investors-sitting-003509817.html
 Bullish
Yahoo News
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
https://finance.yahoo.com/news/mesoblast-limited-meso-loses-5-143502783.html
 Bullish
Yahoo News
5 Stocks to Ride the Santa Claus Rally
https://finance.yahoo.com/news/5-stocks-ride-santa-claus-143800307.html
 Bullish

Mesoblast Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Mesoblast and other traded companies coverage with news coverage. We help investors stay connected with Mesoblast headlines for the 14th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Mesoblast Stock performance. Please note that trading solely based on the Mesoblast hype is not for everyone as timely availability and quick action are needed to avoid losses.
Mesoblast's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Mesoblast investors visualize upcoming and past events in order to time the market based on Mesoblast noise-free hype analysis.
Mesoblast stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Mesoblast earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Mesoblast that are available to investors today. That information is available publicly through Mesoblast media outlets and privately through word of mouth or via Mesoblast internal channels. However, regardless of the origin, that massive amount of Mesoblast data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Mesoblast news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Mesoblast relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Mesoblast's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Mesoblast alpha.

Mesoblast Largest EPS Surprises

Earnings surprises can significantly impact Mesoblast's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-02-27
2022-12-31-0.1802-0.15740.022812 
2022-05-31
2022-03-31-0.13-0.16-0.0323 
2020-05-27
2020-03-31-0.17-0.140.0317 
2020-02-26
2019-12-31-0.2-0.23-0.0315 
2016-11-14
2016-09-30-0.29-0.260.0310 
2023-05-25
2023-03-31-0.17-0.130.0423 
View All Earnings Estimates

Mesoblast Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Mesoblast Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Gurufocus Stories at Macroaxis
12th of March 2025
Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
at gurufocus.com 
news
6th of March 2025
Mesoblast Joins SPASX 200 Index
at finnewsnetwork.com.au 
fool News
3rd of March 2025
Up 810 percent in a year, the Mesoblast share price is surging again on Monday. Heres why
at fool.com.au 
Yahoo News
26th of February 2025
Mesoblast Limited Could Find a Support Soon, Heres Why You Should Buy the Stock Now
at finance.yahoo.com 
Gurufocus Stories at Macroaxis
24th of February 2025
Mesoblast Ltd Appoints Dr. Gregory George to Board of Directors
at gurufocus.com 
Gurufocus Stories at Macroaxis
14th of February 2025
Mesoblast Ltd Showcases FDA-Approved Ryoncil at Prestigi
at gurufocus.com 
news
31st of January 2025
Mesoblast Advances Ryoncil Launch Following FDA Approval
at kalkinemedia.com 
Google News at Macroaxis
30th of January 2025
1,000 invested in Mesoblast shares at the start of 2024 is now worth - The Motley Fool Aus...
at news.google.com 
Gurufocus Stories at Macroaxis
19th of December 2024
Mesoblasts RYONCIL is the First U.S. FDA-Approved Mesenchymal
at gurufocus.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mesoblast in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mesoblast's short interest history, or implied volatility extrapolated from Mesoblast options trading.
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out Mesoblast Backtesting and Mesoblast Hype Analysis.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
0.06
Quarterly Revenue Growth
(0.41)
Return On Assets
(0.05)
Return On Equity
(0.18)
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.